FDA recall record

Abrams Royal Pharmacy II CORTISOL-MC, 10mg CAP recall — FDA D-1231-2015

Failed Content Uniformity Specifications: Failed Uniformity of Dosage Units specifications.

Class IIIclassification
D-1231-2015official record ID
Jul 15, 2015report date

Recall record at a glance

Official recordD-1231-2015
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmAbrams Royal Pharmacy II, LLC
Report dateJul 15, 2015
Recall initiation dateJun 23, 2015
Quantity30 count: 5 Bottles; 90 count: 2 Bottles
LocationPlano, TX, United States

Official product description

CORTISOL-MC, 10mg CAP, packaged in 30 and 90 count bottles, Rx Only, ABRAMS ROYAL pharmacy II, 4909 W Park Blvd, Suite 177, Plano, TX 75093 --- NDC 88888-0043-31

Why the product was recalled

Failed Content Uniformity Specifications: Failed Uniformity of Dosage Units specifications.

Distribution information

United States including: Texas

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.